Novo Nordisk shares PLUNGE after announcing that a pill version of Ozempic failed to slow the progression of Alzheimer's disease in two late-stage studies. Bloomberg's Madison Muller discusses the story on "Bloomberg Markets" with Scarlet Fu.

Bloomberg videos, provided by MT Newswires